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Abstract
Synbiotic (probiotic bacteria and prebiotic) has beneficial effects on the gastrointestinal tract. This study was designed to investigate
the effect of synbiotic supplementation on the growth ofmild tomoderate failure to thrive (FTT) children. A randomized, triple-blind,
placebo-controlled trial was conducted involving 80 children aged 2–5 years with mild to moderate FTT, who were assigned at
random to receive synbiotic supplementation (109 colony-forming units) or placebo for 30 days. The weights, height, and BMI were
recorded in a structured diary, and the questionnaires were completed to monitor the numbers of infection episodes, gastrointestinal
problems, admission to hospital, and appetite improvement during the study. Sixty-nine children completed the study. There were no
differences in the demographic characteristic between the two groups. The mean weight was similar at baseline. After 30 days of
intervention, the mean weight of the participants in the synbiotic group increased significantly than those in the placebo group (600 ±
37 vs. 74 ± 32 g/month P 0.000). BMI changes in synbiotic and placebo group were 0.44 and 0.07 kg/m2, and that the differences
among the two groups were significant.(P 0.045) Furthermore, the height increment in synbiotic and placebo group was 0.41 and
0.37 cm respectively with no significant difference (P 0.761). Administration of 30-day synbiotic supplementation may significantly
improve weight and BMI in Iranian children with mild to moderate FTT, but there is no effect on the height in this study. Further
studies should be designed to found out the effect of synbiotic on growth parameters in undernourished and well-nourished children.
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Introduction
Malnutrition in children is still a major public health issue
across the world, particularly in developing countries.
According to the 2011 WHO Report, 27% of children under
5 years old are underweight [1].
In Iran as a developing country, 15.7% of children are
underweight and 18.9% are stunted [2]. Under nutrition is a
major risk factor of mortality and morbidity among the chil-
dren under 5 years [3]. Failure to thrive (FTT) patients may
deal with recurrent gastrointestinal and respiratory tract infec-
tions, cognitive defects, developmental delay, and emotional
and socioeconomic problems [4]. So, it can cause a heavy
economic burden on the health system [5].
Adequate nutrition is important for optimal growth and
development [6]. Insufficient caloric intake and nutrient ab-
sorption are the common causes of FTT [7]. Macronutrient
and micronutrients deficiencies through different ways such
as poor nutrition and infectious disorders are the major cause
of under nutrition [3, 8]. So prevention and treatment of this
problemmay be of value. Therefore, finding an effective, safe,
and available treatment for weight gain in children with mal-
nutrition is important.
Nowadays, there is a trend in consumption of probiotics for
weight gain because of their beneficial effects on micronutri-
ent and macronutrient absorption [9]. It is shown that
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widespread ingestion of probiotics may promote weight gain
by changing the intestinal flora [10].
The other beneficial effects of probiotics is on infectious
diarrhea and dysentery [11, 12], antibiotic associated diarrhea
[13], upper respiratory infections [14, 15], necrotizing entero-
colitis in very low birth weight infants [16–18], irritable bowel
syndrome (IBS) [19], childhood atopy [20], colic [21], anemia
[22] and children growth pattern [23].
Probiotics are live microorganisms that when administered
in sufficient amounts may cause a health benefit on the host
[24]. They work by regulating the immune system, inhibiting
the pathogen adherent to gut epithelium, and improving nutri-
ent absorption [9].
Prebiotics are nondigestible substances that provide a ben-
eficial physiological effect for the host by selectively stimu-
lating the favorable growth or activity of a limited number of
indigenous bacteria. Prebiotics increase the absorption of min-
erals and trace elements [25].
The combination of probiotics and prebiotics named
synbiotics exerts a beneficial effect beyond their own ef-
fect [26].
Because of the beneficial effects of synbiotics on nutrient
absorption and immune system, different studies have evalu-
ated the effects of synbiotic supplementation on growth pa-
rameters that the results were conflicting, so this study was
established to evaluate the growth of undernourished children
consuming a synbiotics or placebo sachet with weight, height,
and BMI as the primary outcomes. As secondary outcomes,
the study evaluated infectious episodes and gastrointestinal
(GI) problems as well as the appetite improvement.
Materials and Methods
This study was a triple-blind, placebo-controlled, randomized
nutritional intervention study conducted in Khatamolanbia
Clinic, Shahid Sadoughi University of Medical Sciences,
Yazd, Iran, from 2016 to 2017. Eighty children of age 24 to
59months with mild tomoderate undernourishment whowere
normal on the other parts of physical were recruited. The se-
verity of malnutrition was determined according to the Gomez
classification that mild, moderate, and severe status has been
equivalent to 75–90%, 60–74%, and less than 60% of stan-
dard weight, respectively [27]. From a total of 80 children
with mild to moderate FTT, 11 were excluded that the patients
according to the exclusion criteria (6), loss of follow-up (3),
and poor compliance (2).
Exclusion criteria were antibiotic consumption 2 weeks
prior the study, diarrhea at the time of study, any congenital
abnormality or chromosomal disorder, ICU admission more
than 3 days, birth weight under 2500 g, and gestational age
under 37 weeks.
The study protocol was approved by the research and eth-
ical committee of Shahid Sadoughi University of Medical
Sciences. Written informed consent was obtained from the
patients’ parents or guardians.
The patients were randomly divided in two groups:
synbiotic and control, using a random table numbers. The
patients in the two groups were matched by age, sex, and
weight. The case group was given a synbiotic sachet
(Kidilact) which contained 109 colony-forming unit (CFU)
of 7 effective strains including Lactobacillus acidophilus,
Lactobacillus rhamnosus, Lactobacillus bulgaricus,
Lac tobac i l l u s case i , Bi f idobac t e r ium in fan t i s ,
Bifidobacterium breve, and Streptococcus thermophilus, as
probiotics, and a prebiotic Fructooligosaccharides 1 g daily
for 30 days. The children in the control group were given a
placebo sachet daily which had a similar taste, smell, and
appearance with synbiotic sachet and were supplied by the
same company. The sachets were in the form of a powder
reconstituted by parents with 5–10 ml of water and adminis-
tered orally as a suspension. Products were manufactured ac-
cording to current good manufacturing practices, and were
packaged and coded at the Zist Takhmir Company. The pedi-
atrician, parents, pharmacy, and statistical analyzer were not
aware of the codes of synbiotic or placebo. The parents re-
ceived the sachets at first visit by clinic pharmacy.
All patients were visited by a pediatrician at first. Physical
examination and anthropometric measurements were recorded
at first by the pediatrician as well as after 30 days of interven-
tion by the same pediatrician. The children were weighed
(measured with a Seca [Unicap, Australia] digital scale with
an accuracy of 0.1 kg) and height measured (measured with a
Somatometer [Stanley Mabo, Depose, France] with an accu-
racy of 0.1 cm) in light clothing without shoes using a digital
standing scale by the same physician. Bodymass index (BMI)
was calculated as weight (kilograms) divided by height
(meters) squared. In this study, we measured average of
weight gain and other growth parameters in two groups of
case and control to compare weight gain velocity (weight gain
as gr/month), height increment velocity (height increment as
cm/month), and BMI velocity (BMI difference as kg/m2/
month) during the study.
Compliance of intake was assessed by pediatric assistant
every week by telephone call. Furthermore, the parents were
asked to return the empty boxes of sachets for assuring the
compliance.
Moreover, numbers of upper respiratory disorders, gastro-
intestinal problems, antibiotic consumption, and appetite im-
provement and any adverse reaction to the medication were
assessed weekly by telephone call.
Considering confidence level of 95% and a power of 80%,
the sample size was estimated as minimum of 31 patients in
each group. Results were reported as mean ± standard devia-
tion (SD) for the quantitative variables. The groups were
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compared using the Student’s t test and the chi-square test (or
Fisher’s exact test if required) for the categorical variables.
All the statistical analyses were performed using SPSS ver-
sion 19.0 (SPSS Inc., Chicago, IL, USA). A P value < 0.05
was considered as statistically significant.
After finishing the statistical analysis, breaking the codes
were done.
Results
Of 80 FTT children, 69 patients met the inclusion criteria and
completed the study.
Forty one (59%) were females and 28 (41%) were males.
Of these, 37 patients (24 girls, 13 boys) were in the synbiotic
group and 32 patients (17 girls, 15 boys) were in the placebo
group.
Age range was between 24 and 59months with a median of
43 months old. Fifty six of 69 patients (81%) were mild under
nutrition and 13 (19%) were moderate under nutrition.
The demographic characteristics of the 69 patients who
completed the study are presented in Table 1. There was no
significant difference in the weight, age, gender, and mode of
delivery distribution among the two groups.
The mean initial children weight was 12.41 ± 1.59 kg
(range 8.5–16 kg). While mean initial weight and follow-up
weight, in the synbiotic group, were 12.05 ± 1.63 kg and
12.65 ± 1.66 kg, respectively. The mean weight of children
in placebo group at the first and at the end of intervention
was 12.53 ± 1.63 kg and 12.60 ± 1.51 kg respectively.
The average weight velocity after treatment was found to
be significantly higher in the case group as compared to the
control group (600 g vs. 74 g) (P 0.000) (Table 2). On further
analysis, it was found that the effect of synbiotics on weight
gain was not confined to a particular age group or malnutrition
subgroups.
BMI in the case group at the first and at the end of this
study was 13.68 ± .94 and 14.12 ± 1.11 respectively and in the
control group was 13.82 ± .74 and 13.89 ± .63 respectively.
BMI changes in the case group were statistically significant
than the control group (P 0.045).
The mean height in the case group before and after treat-
ment was 94.89 ± 5.95 and 95.30 ± 5.02 cm and in the control
group was 95.28 ± 6.40 and 95.65 ± 5.97 respectively. The
mean height increment in the synbiotic and control group
was not statistically different (0.41 vs. 0.37 cm, P 0.761).
No difference on infectious disease episodes was seen in
the two groups after 30 days of synbiotic intervention, where-
as infection episodes in synbiotic and placebo group were 7
(20%) and 8 (27.58%) respectively (P 0.845).
GI problems occurred in the synbiotic and placebo group in
3 (9.37%) and 5 (13.51%) children respectively (P 0.575).
No statistical significance was observed between the
synbiotic and placebo groups in antibiotic consumption (4
vs. 6 respectively) (P 0.52) (Table 3).
Sixteen patients (24.51%) reported appetite improvement,
whereas 7 (20.91%) were in the synbiotic group and
9(28.12%) were in the control group. The differences among
the two groups were not statistically significant (P 0.211)
(Table 3).
Discussion
The present study evaluated the efficacy of 30-days adminis-
tration of synbiotic supplementation on growth parameters in
mild to moderate FTT children. We found that synbiotics can
be beneficial in terms of weight and BMI gain, particularly in
children who are under-nourished after 30 days of
Table 1 Demographic data of
children in the case and control
group
Variables Case group N(%) Control group N(%) P value
Gender Male 13(35.13) 15(46.87) 0.126
Female 24(64.86) 17(53.12)
Mode of delivery NVD 26(70.27) 25(78.12) 0.256
C/S 11(29.72) 7(21.87)
Age (months) 24–36 9(24.32) 8(25) 0.715
36–48 12(32.43) 13(40.62)
48–59 16(43.24) 11(34.37)
Malnutrition severity Mild 29(78.37) 27(84.37) 0.656
Moderate 8(21.62) 5(15.62)
Table 2 Effect of synbiotic supplementation on anthropometric






Weight velocity Δ(gr/month) 600 ± 201.86 74 ± 63 0.000
Height velocityΔ (cm/month) .41 ± .75 0.37 ± .91 0.761
BMI velocityΔ (kg/m2)/month .44 ± .39 0.07 ± .05 0.045
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intervention, with a similar efficacy to other clinical studies.
[15, 22, 28] However, synbiotic did not have a significant
effect on frequency of infection and GI problems.
The product used in this study was Kidilact sachet which
contained Lactobacillus acidophilus, Lactobacillus
rhamnosus, Lactobacillus bulgaricus, Lactobacillus casei,
Bifidobacterium infantis, Bifidobacterium breve, and
Strep tococcus thermophi lus , as probio t ics , and
Fructooligosaccharides as a prebiotic. The reasons we chose
this product were that it was well tolerated in children and also
because of probiotic Bifidobacterium and Lactobacillusmajor
benefits. As in a study by Million et al. [29], they concluded
that different Lactobacillus species are associated with differ-
ent effects on weight that are host-specific. They showed that
Lactobacillus acidophilus administration causes a significant
weight gain in human and in animal, while Lactobacillus
gasseriwas associated with weight loss both in obese humans
and in animals. Also in our study, the synbiotic sachet
consisted of Lactobacillus acidophilus but not Lactobacillus
gasseri.
The effect of synbiotic supplementation on weight, height,
and BMI that are important anthropometric parameters for
child growth was reported in different studies. In various stud-
ies, it is shown that probiotics may promote weight gain [15,
28], while in the other studies, weight loss [30, 31] was ob-
served as a result of synbiotic consumption. On the other
hand, some other studies failed to show efficacy of probiotics
and synbiotics on weight [38–40.] The results of these studies
were different based on obesity or malnutrition of the cases.
Hence, in a study by Ipar [32], they concluded that synbiotic
can help obese children to lose weight. Also, age of the par-
ticipants has an important role in the effectiveness of
probiotics, while in a study by Dror et al. [23], synbiotics
caused weight loss in adults and weight gain in children.
The different effects of synbiotics in the studies may be due
to variation in the dose and strains of probiotics, duration of
intervention, characteristics of participants, statistical analy-
ses, and different geographic regions.
It is proven that the gut senses alterations in nutrient avail-
ability and subsequently modulates the nutrient absorption.
[33, 34] Also, the different effect of probiotics on obese and
undernourished children may be due to gut microbiota differ-
ences between overweight and lean children [35].
Furthermore, the different gut microbiota may influence calo-
ric intake, intestinal absorption, and energy balance [34].
In this study, we reported the positive effect of synbiotic on
weight and BMI which was in accordance with the studies
conducted by He [15], Famouri [28], Kerac [36], and Saran
[37] on undernourished children and contrary to the studies by
Gil-Compos [38], Gibson [39], and Scalabrin [40] that report-
ed no effect of synbiotic consumption on weight gain in well-
nourished children [41, 42].
It seems that different gut microbiota composition in un-
dernourished and well-nourished children and also living in
developed or developing countries may play an important role
on the effects that synbiotic may have [43, 44].
In developed countries, synbiotic supplementation had no
effect on weight gain [38–42, 45]. However, it had a signifi-
cant effect on weight promotion in children living in develop-
ing countries [15, 22, 28, 37, 46].
Moreover, the composition of gut microbiota may vary due
patient’s age [47], while in the studies that the subjects were
infants or individuals younger than 7 months old, the effect of
synbiotics on weight gain has not been established [38–42,
45]. But in the studies conducted on children with 1–5 years
of age, the synbiotics supplementation had a significant effect
on weight improvement [15, 22, 28, 37, 46].
Our study was done in Iran as a developing country and
was conducted on undernourished children aged 2–5 years, so
the results of our study were in accordance with the other
studies that were done on undernourished children in devel-
oping countries.
In our study, we did not find any effect of synbiotics on
height, while in studies by He [15], Saran [37], and Silva [48],
they found a significant difference in height of the children. In
He et al. [15], the children in the probiotic group had a change
in height-for-age z score at 9 months of supplementation, and
in Saran et al., the children in the probiotic group grewmore in
length compared to the control group, after 6 months. In Silva
et al.’s study, height increment was shown after 101 days of
probiotics consumption. In our study we just used 30 days of
synbiotic, so short duration of synbiotic may not conclude the
effectiveness of synbiotic on height.
Although it is described that lactobacillus/Bifidobacterium
improved protection against rotavirus diarrhea and infection in
pediatrics [49], in this study we have not seen any effect of
synbiotic on prevention of infection episodes and GI
problems.
The limitation of our study was exclusion of sever mal-
nourished children, since they need additional treatments.
The other limitation of this study was that we did not assess
dietary intake of participants along the study and were there-
fore unable to control for this variable.
Table 3 Effect of synbiotic supplementation on infection episodes and
diarrhea among 2- to 5-year-old FTT children
Variables Case group (37) Control group (32) P value
No. cases % No. cases %
URTI 7 20 8 27.58 0.845
GI problems 3 9.37 5 13.51 0.575
Appetite improvement 7 20.91 9 28.12 0.211
Antibiotic consumption 4 10.81 6 18.75 0.520
URTI upper respiratory tract infection, GI gastrointestinal
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Conclusion
In conclusion, this study provides evidence that short course
of synbiotic supplementation may cause weight and BMI gain
in mild to moderate undernourished children.
Further studies are needed to better understand the mecha-
nisms of synbiotics’ effects. It is recommended to evaluate gut
microbiota and also the levels of micronutrient and macronu-
trient in plasma before and after the treatment.
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